Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for Cisplatin-Induced Toxicities
NCT06297369Phase 2Recruiting
- Sponsor
- Ain Shams University
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acetylcysteine in cisplatin-induced ototoxicity, cisplatin-induced nephrotoxicity (CIN) and peripheral neuropathy (2 arms), sponsored by Ain Shams University. Primary endpoint: Occurrence of cisplatin-induced ototoxicity (hearing loss). Started Feb 2024; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
cisplatin-induced ototoxicitycisplatin-induced nephrotoxicity (CIN)peripheral neuropathy
Beyond the preview
Go deeper on NCT06297369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297369.